|Day's Range||16.20 - 16.55|
|52 Week Range||10.98 - 18.00|
|PE Ratio (TTM)||-54.28|
|Earnings Date||Aug 2, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||21.50|
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com. All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this release is provided only as of the date of this release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.
Conference Call and Webcast to Follow WASHINGTON , July 17, 2017 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced it will release results for the second quarter of 2017 ...
The Zacks Analyst Blog Highlights: Merck, Celgene, Gilead Sciences, Seattle Genetics and Vanda Pharmaceuticals